Protocol
13-035
Full Title
A Phase 1, Open-label, Dose-escalation Study of SNX-5422 and Erlotinib in Subjects with Lung Adenocarcinoma with "Acquired Resistance" to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Purpose
Erlotinib is the typical first treatment for patients with lung cancers that have the EGFR mutation. The cancer usually shrinks at first, but after awhile, it begins to grow again. The purpose of this study is to find the best dose of the combination of an investigational drug called SNX-5422 and erlotinib in patients whose lung cancers have started to grow on erlotinib treatment alone. The hope is that giving both drugs together will stop tumors from growing.
SNX-5422 works against cancer by blocking a protein that cancer cells need called HSP90. Laboratory studies have shown that combining SNX-5422 and erlotinib can shrink lung tumors that initially responded to erlotinib but are now growing. SNX-5422 has been assessed alone in patients, but this is the first study to combine SNX-5422 and erlotinib in patients. Both drugs are taken orally (by mouth).
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have lung cancer that has an EGFR mutation.
- Patients must have stage IIIB or stage IV lung cancer that has continued to grow despite erlotinib therapy.
- Patients may have had up to four prior regimens of chemotherapy.
- At least 4 weeks must have passed since any therapy other than erlotinib, including chemotherapy, monoclonal antibody therapy, radiation therapy, or treatment on a clinical trial and entry into the study.
- This study is open to patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Helena Yu at 646-888-4274.
Disease(s)
Lung Cancer, Non-Small Cell
Lung Cancer, Non-Small Cell: Lung Adenocarcinoma
Locations
Related Diseases
